CockettFBThomasMLNegusD.Iliac vein compression – its relation to iliofemoral thrombosis and the post-thrombotic syndrome.Br Med J1967;
2: 14–19.
2.
KahnSRComerotaAJCushmanM, et al. The postthrombotic syndrome: evidence based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014; 130: 1636–61.
WittensCDaviesAHBroholmR, et al.
Editor's choice – management of chronic venous disease.Eur J Vasc Endovasc Surg2015;
49: 678–737.
5.
RajuSOwenSNeglenP.The clinical impact of iliac venous stents in the management of chronic venous insufficiency.J Vasc Surg2002;
35: 8e14.
6.
TosenovskyP.One-year results of iliocaval stenting.Ann Vasc Surg2019;
59: 208–216.
7.
EijgenraamPten CateHten Cate-HoekAJ, et al.
Venous stenting after deep venous thrombosis and antithrombotic therapy: a systematic review.Rev Vasc Med2014;
2: 88–97.
8.
PadrnosLJGarciaD.May-Thurner syndrome and thrombosis: a systematic review of antithrombotic use after endovascular stent placement.Res Pract Thromb Haemost2018;
3: 70–78.
9.
EndoMJahangiriYHorikawaM, et al.
Antiplatelet therapy is associated with stent patency after iliocaval venous stenting.CardioVasc Intervent Radiol2018;
41: 1691.
10.
LangwieserNBernlochnerIWustrowIK, et al.
Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction.Phlebology2016;
31: 430–437.
11.
MilinisKThaparAShalhoubJ, et al.
Antithrombotic therapy following venous stenting: International Delphi Consensus.Eur J Vasc Endovasc Surg2018;
55: 537–544.
12.
National Institute for Health and Care Excellence.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE Guideline, pp.12–15, https://www.nice.org.uk/guidance/cg144 (2015, accessed 10 January 2020).
13.
CapriniJAGoldshteynSGlaseCJ, et al.
Thrombophilia testing in patients with venous thrombosis.Eur J Vasc Endovasc Surg2005;
30: 550–555.
14.
MekajYHMekajAYDuciSB, et al.
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag2015;
11: 967–977.